Nanotherapies are emerging rapidly as options to treat cardiovascular disease. However, insufficient and heterogeneous delivery remain critical issues. Novel strategies to boost targeted delivery of systemically administered nanoparticles by optimizing the particle physical properties or using immune cells as carriers promise to increase nanotherapeutic effectiveness in cardiovascular and other inflammatory diseases.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fish, M. B. et al. Deformable microparticles for shuttling nanoparticles to the vascular wall. Sci. Adv. 7, eabe0143 (2021).
Huang, S. S. et al. Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer. Sci. Adv. 7, eabf2400 (2021).
Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).
Kanthi, Y., de la Zerda, A. & Smith, B. R. Nanotherapeutic shots through the heart of plaque. ACS Nano 14, 1236–1242 (2020).
Smith, B. R. & Gambhir, S. S. Nanomaterials for in vivo imaging. Chem. Rev. 117, 901–986 (2017).
Smith, B. R. et al. Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett. 8, 2599–2606 (2008).
Namdee, K., Thompson, A. J., Charoenphol, P. & Eniola-Adefeso, O. Margination propensity of vascular-targeted spheres from blood flow in a microfluidic model of human microvessels. Langmuir 29, 2530–2535 (2013).
Smith, B. R. et al. Selective uptake of single walled carbon nanotubes by circulating monocytes for enhanced tumour delivery. Nat. Nanotechnol. 9, 481–487 (2014).
Sofias, A. M. et al. Cyclic arginine–glycine–aspartate-decorated lipid nanoparticle targeting toward inflammatory lesions involves hitchhiking with phagocytes. Adv. Sci. 8, 2100370 (2021).
Flores, A. M. et al. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis. Nat. Nanotechnol. 15, 154–161 (2020).
The author is grateful to the funding agencies AHA Transformational Project Award 18TPA34230113 and NIH grant R01 CA244491, and to Y. Zhang (MSU, USA) for initial figure preparation and A. Alessio for discussion (MSU, USA).
The author declares no competing interests.
About this article
Cite this article
Smith, B.R. Nanotherapeutics for cardiovascular disease. Nat Rev Cardiol 18, 617–618 (2021). https://doi.org/10.1038/s41569-021-00594-5